Cullinan Therapeutics, Inc. (CGEM) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$241.65M | -22.7% |
| 2024 | -$196.92M | -3.1% |
| 2023 | -$191.09M | -232.1% |
| 2022 | $144.65M | +312.9% |
| 2021 | -$67.95M | -12.6% |
| 2020 | -$60.34M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$241.65M | -22.7% |
| 2024 | -$196.92M | -3.1% |
| 2023 | -$191.09M | -232.1% |
| 2022 | $144.65M | +312.9% |
| 2021 | -$67.95M | -12.6% |
| 2020 | -$60.34M | — |